Q-omics provides the consensus-scored HSPD1P9 profile across patient tissues and cancer cell-line models. HSPD1P9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HSPD1P9 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, HSPD1P9 RNA expression shows 7,648 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UVM, LUSC, and LAML as cancer lineages where HSPD1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPD1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPD1P9 survival associations across molecular data types. HSPD1P9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPD1P9 RNA expression–survival associations across cancer types. High HSPD1P9 expression shows unfavorable associations in UVM, ACC, STAD and CHOL, but favorable associations in BRCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HSPD1P9 RNA expression.
This table summarizes HSPD1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HSPD1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPD1P9 shows lower tumor expression in LUSC and BRCA and higher tumor expression in PAAD, KIRP and KICH. The LUSC box plot shows higher HSPD1P9 RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .003).
This table shows molecular features associated with HSPD1P9 in patient tissues and cancer cell lines. In patient samples, HSPD1P9 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
